Affirms U.S. LINZESS Net Sales view of $800M – $850M. High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma: Hold Rating Maintained Amid Revenue Uncertainty and Long-term Concerns
- IRWD Earnings this Week: How Will it Perform?
- Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M
- Ironwood downgraded to Hold from Buy at Craig-Hallum
- Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options